Table 1. Patient characteristics.
| Number of subjects | 13 |
|---|---|
| Age (years) | 56 (± 9.8) |
| Gender, F:M | 7:6 |
| Smoking history (number) | Never: 7 |
| Ex: 6 | |
| Current: 0 | |
| Asthma duration (years) | 3.5 (1.6–13.4) |
| Asthma medication | SABA: 3 |
| ICS: 1 | |
| ICS/LABA: 3 | |
| ICS/LABA/LTRA: 1 | |
| ICS/LABA/LTRA/TP: 2 | |
| ICS/LABA/LTRA/TP/OCS: 2 | |
| ICS/LABA/LTRA/TP/OCS/anti-IgE: 1 | |
| Asthma severity at stable (number) | Well-controlled: 8 |
| Partly controlled: 5 | |
| Exacerbation severity (number) | Mild or moderate: 9 |
| Severe: 4 | |
| Life-threatening: 0 | |
| Body mass index (kg/m2) | 24.3 (±4.3) |
| Baseline FEV1(% predicted) | 82.2 (±16.4) |
| Baseline FVC (% predicted) | 87.1 (±17.4) |
| Baseline FEV1/FVC (% predicted) | 85.3 (±14.9) |
| Bronchodilator reversibility (%) | 5.4 (±4.7) |
| Baseline FeNO (ppb) | 47.2 (±32.6) |
| Baseline eosinophils in blood (×103 μ/L) | 0.54 (±0.60) |
| Exacerbation eosinophils in blood (×103 μ/L) | 0.83 (±0.99) |
FeNO, fractional exhaled nitric oxide; FEV1; forced expiratory volume 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABA, long-acting beta-2 agonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; SABA, short-acting beta-2 agonist; TP, theophylline